Shrink Nanotechnologies, Inc. (Shrink), a nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering – the StemDisc450™, a high-yield, low cost, patent-pending cell culturing biomedical research tool. Shrink expects to begin offering this product for sale in the latter part of 2010.

"Tissue engineering and cell culturing are high growth areas of the biotechnology field. This trend is being fueled as the idea of 'personalized medicine' – or 'therapeutics and treatments made for you' - becomes a reality. And as the personalized medicine movement grows, biotech and pharmaceutical companies are focusing on the promise of novel research, especially new cellular-based therapies, to help combat cancer, spinal cord injuries, diabetes, Parkinson's and Alzheimer's disease, and many more. StemDisc is a platform for Shrink to offer a growing suite of products that will address an important spectrum of the needs within cellular and tissue engineering technologies and tools," Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

"We have started field testing of our first StemDisc450 prototypes, and we anticipate being able to show time lapse videos of this product performing, and actually developing HESCs (human embryonic stem cells) and IPSCs (induced pluripotent stem cells)," added Baum.

"Shrink is exploring opportunities with established stem cell R&D companies for potential strategic partnerships for the sale and marketing of StemDisc™ products. Our primary target market is the more than 3,000 stem cell research labs and 15,000 biomedical laboratories operating in the United States."